These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38185077)

  • 1. Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update.
    Rodziewicz M; Mendoza-Pinto C; Dyball S; Munguía-Realpozo P; Parker B; Bruce IN
    Semin Arthritis Rheum; 2024 Apr; 65():152346. PubMed ID: 38185077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): A systematic review.
    Pirone C; Mendoza-Pinto C; van der Windt DA; Parker B; O Sullivan M; Bruce IN
    Semin Arthritis Rheum; 2017 Dec; 47(3):384-396. PubMed ID: 28602359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review.
    Mendoza-Pinto C; Pirone C; van der Windt DA; Parker B; Bruce IN
    Semin Arthritis Rheum; 2017 Aug; 47(1):65-78. PubMed ID: 28325471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
    Kaegi C; Wuest B; Crowley C; Boyman O
    Front Immunol; 2021; 12():788830. PubMed ID: 35185862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
    Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
    Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.
    Shah K; Cragg M; Leandro M; Reddy V
    Biologicals; 2021 Jan; 69():1-14. PubMed ID: 33288390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy.
    Bela MM; Espinosa G; Cervera R
    Lupus; 2021 Jan; 30(1):134-140. PubMed ID: 33081591
    [No Abstract]   [Full Text] [Related]  

  • 11. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus.
    Oon S; Huq M; Godfrey T; Nikpour M
    Semin Arthritis Rheum; 2018 Oct; 48(2):221-239. PubMed ID: 29426575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C; Foote S; Jones G
    BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
    Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
    Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
    Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
    BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review.
    Cobo-Ibáñez T; Loza-Santamaría E; Pego-Reigosa JM; Marqués AO; Rúa-Figueroa I; Fernández-Nebro A; Cáliz Cáliz R; López Longo FJ; Muñoz-Fernández S
    Semin Arthritis Rheum; 2014 Oct; 44(2):175-85. PubMed ID: 24830791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
    Reddy V; Jayne D; Close D; Isenberg D
    Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.